Facing Your Fears Adapted for Schools
Principal Investigator: Judy Reaven, PhD / Judy.Reaven@ucdenver.edu Children with ASD are at high risk for developing clinically significant anxiety that interferes with peer relationships, family functioning and participation in academic programming.
Although research has demonstrated the positive impact of modified Cognitive Behavior Therapy (CBT) on anxious symptoms in youth with ASD, substantial disparities in access to psychiatric services exist, particularly for youth from diverse and/or low income families.
Schools are the ideal location to access these services. We are partnering with Cherry Creek School District, Denver Public Schools and Littleton Public Schools for this project. After spending the past year adapting the clinic-based Facing Your Fears (FYF) Program (Reaven et al. 2011 ) for school settings, we are now implementing the program in 9 schools across the three districts. Approximately 30 students with ASD and anxiety have participated in the school based FYF. We are collecting post-treatment data, including exit interviews with all of the school teams.
We will expand the program to 10 schools per district next fall, and look forward to sharing more formal results of this project. Many thanks to our fantastic school partners at each district, as well as the many families who have participated in this project. 
Facing Your Fears Adapted for Adolescents with ASD and ID
Principal Investigator: Audrey Blakeley-Smith, PhD Audrey.Blakeleysmith@ucdenver.edu Our research team received two years of funding from the Organization of Autism Research (OAR) to explore the efficacy of an adapted version of Facing Your Fears (FYF) for adolescents with Autism Spectrum Disorder (ASD) and Intellectual Disabilities (ID).
Nineteen families completed the 14 week cognitive behavioral treatment (CBT) intervention and significant improvements were noted in mood and anxiety symptoms.
We have learned that the intervention may be effective in developing strategies to help teens with ASD/ID to be "brave", face fears, and gain the skills necessary to manage difficult and overwhelming activities. Teens with ASD and ID can change the way they talk to themselves through coping statements (e.g., "I can handle it"), practice ways to calm their bodies (i.e., deep breathing), and create goals that reflect what they want to achieve.
Family, school, and friends can then help support the achievement of these goals by identifying anxiety, supporting strategy use, and coaching brave behavior.
Next steps in this project are to apply for an additional grant to conduct a randomized control trial with a comparison group. In addition, we are interested in providing this treatment as a clinical service within Developmental Pediatrics. This study is designed to evaluate the effects of Cannabidiol (CBD) in children age 5-17 with Autism Spectrum Disorder to determine if there are benefits or risks to symptoms of irritability, aggressive behavior, anxiety, social interactions, repetitive behaviors, and sleep. The study will also evaluate safety and side effects of CBD in children with ASD. CBD is a chemical from the Cannabis (marijuana) plant that acts on receptors in the brain and throughout the body, but does not cause the same psychoactive effects of THC. Study participants will have 6-8 visits over a 26-30 week period, and all participants will receive treatment with both CBD and placebo during this period, with at least 12 weeks of CBD treatment during the study period.
This three-year study is sponsored by the Colorado Department of Health and Environment. Approvals for this study are currently underway. If you are interested in more information in the future, please email your name and contact information to CBDinAutismStudy@childrenscolorado.org. We will contact you once study approvals are completed.
This research proposes to evaluate the safety and efficacy of CBD in youth ages 5 to 17 with ASD with high irritability and aggression. The funding of the study from the state's Medical Marijuana Research Grant Program has been recently highlighted in both The Gazette and The Denver Post. See Study Recruitment Section about how to join this study. Balovaptan is a medication that blocks a hormone receptor in the brain linked to the control of socialization, stress, anxiety and aggression. Males and females age 5-12 with a diagnosis of autism spectrum disorder who have an IQ of 70 or above are eligible to participate. Participants first have a screening visit, and if eligible are then assigned randomly to receive either balovaptan or placebo medication for 24 weeks, with study visits approximately every 6 weeks.
Following participation in the aViation study, participants are eligible for an optional follow-up "open-label" study where everyone is treated with the study medication. The Rocket study is a clinical research study that will help determine if an investigational medicine, called OV101 or gaboxadol, is safe and effective in treating behavioral characteristics commonly present in people with Fragile X syndrome (FXS). The study will test three different doses of OV101. Participation in the Rocket study will last about 21 weeks and include six visits to Children's Hospital Colorado and four phone appointments. COMIRB#: 18-0718. See Study Recruitment Section about how to join this study. The purpose of the CONNECT-FX study is to evaluate the efficacy and safety of an investigational CBD gel (ZYN002). This study is a clinical trial evaluating a novel transdermally delivered CBD (ZYN002) for some common and debilitating behaviors associated with Fragile X. COMIRB#: 18-1480. See Study Recruitment Section about how to join this study.
Research Updates

The eXtraordinarY Babies Study: Researching the Natural History of Health and Neurodevelopment in Infants and Young Children with Sex Chromosome Trisomy
Principal Investigator: Nicole Tartaglia, MD, MS The eXtraordinarY Babies Study evaluates the early health and development of infants and children with sex chromosome disorders. This study follows babies, who were diagnosed with a sex chromosome disorder before being born, from 2-3 months of age every 6-12 months as they grow up. This is an amazing opportunity to learn about the natural history of neurodevelopment, health and early hormonal function in infants with XXY/Klinefelter syndrome, XYY, XXX and other sex chromosome variations.
We hope to identify early predictors of developmental and health outcomes observed in the variability in these conditions from a young age that will allow us to counsel families and develop specific treatment programs for these eXtraordinarY kids. In the study, we will closely evaluate and track developmental skills, medical problems, hormone levels, body composition, and other important factors such as family history, interventions, and family quality of life. The primary objective of this study is to determine the percentage of preschool age children with ADHD who responded positively to stimulants and A2A based on a review of data in the Electronic Health Record (EHR) and to determine if there is a difference in the positive response rate to these two classes of medication. Secondary objectives are to describe type and frequency of adverse effects to stimulants and A2A when prescribed for the treatment of preschool age children for ADHD. This study will involve review of EHR at 7 outpatient developmental and behavioral pediatrics practices and enroll up to 1700 children less than 72 months of age with a diagnosis of ADHD who are seen in the above practices. Approximately 850 charts of children treated with stimulants or A2A will be manually reviewed.
The Role of ADOS in Diagnosis of Autism by Developmental Behavioral Pediatricians
PI: Sandra Friedman, MD, MPH / Sandra.Friedman@childrenscolorado.org This is a prospective study to determine the frequency with which results of the ADOS-2 alters the diagnostic conclusion of developmental-behavioral pediatricians evaluating a child age 18 months to 5 years, 11 months for possible ASD. This study involves 8 of the 14 DBPNet sites.
It is anticipated that three hundred fifty children ages 18 months to 5 years, 11 months who are referred to a DBP clinic for possible ASD will be enrolled in the study to yield 300 evaluable cases. The primary objective of this study is to determine if families will adhere to a Crisis Plan, and, if followed, if the Crisis Plan is effective in decreasing occurrence of crises, crisis severity, and emergency service utilization.
Study to Explore Early Development (SEED 3)
We are enrolling parents of an individual who has both a neurodevelopmental diagnosis AND a psychiatric or behavioral diagnosis. This study has been designed to learn more about young children who have an extra X or Y chromosome, also referred to as 'sex chromosome trisomies' (SCTs). We want to learn more about the early health and development in SCTs. This study includes tests of neurodevelopment, behavior and physiology in young children with a SCT. This study will help us find out if there are early predictors for future outcomes of learning, behavior, motor skills, social skills, and overall health. It will also help to develop recommendations for care of young children with SCT. The Study to Explore Early Development (SEED III) is a multi-year study to help identify factors that may put children at risk for autism spectrum disorders (ASDs) and other developmental disabilities.
By invitation only, we are enrolling children: 1. Were born in and currently live in one of the eight SEED study counties. Some foods are designed to support children's growth and development. The purpose of this research is to understand how children respond to one such food. 
